IN2012DN03032A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03032A
IN2012DN03032A IN3032DEN2012A IN2012DN03032A IN 2012DN03032 A IN2012DN03032 A IN 2012DN03032A IN 3032DEN2012 A IN3032DEN2012 A IN 3032DEN2012A IN 2012DN03032 A IN2012DN03032 A IN 2012DN03032A
Authority
IN
India
Prior art keywords
receptor antagonist
arb
salts
manufacture
processes
Prior art date
Application number
Other languages
English (en)
Inventor
Gottfried Sedelmeier
Florian Andreas Rampf
Dominique Grimler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41716392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03032(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2012DN03032A publication Critical patent/IN2012DN03032A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/32Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/32Separation; Purification; Stabilisation; Use of additives
    • C07C253/34Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IN3032DEN2012 2009-10-27 2010-10-25 IN2012DN03032A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09174264A EP2316821A1 (fr) 2009-10-27 2009-10-27 Procédé pour la fabrication de composés organiques
PCT/EP2010/066041 WO2011051213A1 (fr) 2009-10-27 2010-10-25 Procédé de fabrication de composés organiques

Publications (1)

Publication Number Publication Date
IN2012DN03032A true IN2012DN03032A (fr) 2015-07-31

Family

ID=41716392

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3032DEN2012 IN2012DN03032A (fr) 2009-10-27 2010-10-25

Country Status (23)

Country Link
US (1) US20120238761A1 (fr)
EP (2) EP2316821A1 (fr)
JP (1) JP2013508436A (fr)
KR (1) KR20120098652A (fr)
CN (1) CN102596899A (fr)
AR (1) AR079104A1 (fr)
AU (1) AU2010311636B2 (fr)
BR (1) BR112012009815A2 (fr)
CA (1) CA2777031A1 (fr)
CL (1) CL2012001081A1 (fr)
CO (1) CO6531487A2 (fr)
EC (1) ECSP12011833A (fr)
IL (1) IL219111A0 (fr)
IN (1) IN2012DN03032A (fr)
MA (1) MA33692B1 (fr)
MX (1) MX2012005025A (fr)
NZ (1) NZ599218A (fr)
PE (1) PE20121501A1 (fr)
RU (1) RU2012121591A (fr)
TN (1) TN2012000154A1 (fr)
TW (1) TW201124389A (fr)
WO (1) WO2011051213A1 (fr)
ZA (1) ZA201202490B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102321038B (zh) * 2011-07-11 2014-03-26 安徽省虹升生物科技有限公司 一种改进的制备缬沙坦方法
FR2981077B1 (fr) * 2011-10-11 2013-11-01 Michelin Soc Tech Methode pour preparer un melange maitre d'elastomere dienique et de silice
US10745363B2 (en) 2016-09-02 2020-08-18 Nanjing Noratech Pharmaceuticals Co., Ltd Crystal forms of valsartan disodium salt
CN110078640B (zh) * 2019-03-29 2022-04-05 浙江美诺华药物化学有限公司 一种缬沙坦中间体的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874867A (en) 1987-05-22 1989-10-17 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
DK0443983T3 (da) 1990-02-19 1996-03-18 Ciba Geigy Ag Acrylforbindelser
JPH04297466A (ja) 1990-06-22 1992-10-21 Nippon Shinyaku Co Ltd テトラゾール誘導体及び医薬
GB9222700D0 (en) * 1992-10-29 1992-12-09 Smithkline Beecham Plc Chemical compounds
GB0222056D0 (en) 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
HRP20030965A2 (en) * 2003-11-24 2005-08-31 Belupo - Lijekovi I Kozmetika D.D. Process for production of (s)-n-pentanoyl-n-[[2'-(
EP1714963A1 (fr) * 2005-04-19 2006-10-25 IPCA Laboratories Limited Procédé pour la préparation du Valsartan et de ses intermédiaires
CA2619955A1 (fr) * 2005-08-22 2007-03-22 Alembic Limited Procede de preparation de valsartan
WO2008004110A2 (fr) * 2006-07-03 2008-01-10 Aurobindo Pharma Limited Procédé amélioré de préparation d'un antagoniste de l'angiotensine ii
CN101450917B (zh) * 2007-12-06 2012-07-11 浙江海正药业股份有限公司 缬沙坦的合成方法
US7943794B2 (en) * 2008-02-13 2011-05-17 Ranbaxy Laboratories Limited Processes for the preparation of intermediates of valsartan

Also Published As

Publication number Publication date
EP2493848A1 (fr) 2012-09-05
CA2777031A1 (fr) 2011-05-05
CO6531487A2 (es) 2012-09-28
TW201124389A (en) 2011-07-16
IL219111A0 (en) 2012-06-28
KR20120098652A (ko) 2012-09-05
NZ599218A (en) 2014-02-28
EP2316821A1 (fr) 2011-05-04
AR079104A1 (es) 2011-12-28
AU2010311636B2 (en) 2014-03-06
CN102596899A (zh) 2012-07-18
TN2012000154A1 (en) 2013-12-12
MA33692B1 (fr) 2012-10-01
PE20121501A1 (es) 2012-11-15
AU2010311636A1 (en) 2012-05-03
ZA201202490B (en) 2012-12-27
BR112012009815A2 (pt) 2016-10-18
JP2013508436A (ja) 2013-03-07
ECSP12011833A (es) 2012-06-29
US20120238761A1 (en) 2012-09-20
RU2012121591A (ru) 2013-12-10
WO2011051213A1 (fr) 2011-05-05
CL2012001081A1 (es) 2013-06-14
MX2012005025A (es) 2012-06-08

Similar Documents

Publication Publication Date Title
TN2011000673A1 (en) Bace inhibitors
WO2010070658A3 (fr) Procédé amélioré de synthèse d'antagonistes de récepteur de l'endothéline
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
UA115136C2 (uk) Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1
IN2012DN02642A (fr)
WO2011022596A3 (fr) Préparation de bazédoxifène et de ses sels
EP2540796A4 (fr) LUMINOPHORE ß-SIALON, SES UTILISATIONS, PROCÉDÉ DE FABRICATION DU LUMINOPHORE ß-SIALON
CL2009000503A1 (es) Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida.
JO2887B1 (en) Spiro-pyridine compounds as ORL-1 receptor antagonists
WO2013098833A3 (fr) Procédés et intermédiaires destinés à la préparation de rivaroxaban
MX2010009003A (es) Ciclohexanodimetanamina por aminacion directa de ciclohexanodimetanol.
UA105785C2 (uk) Спосіб очищення ліпопептидів
BR112012009823A2 (pt) poliuretano dispersível em água
GEP20135903B (en) Method of (1s, 2r)-milnacipran synthesis
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
MX2010000724A (es) Metodo para reducir presion intracraneal.
WO2012015999A3 (fr) Procédé de préparation de mésylate d'imatinib
UA106619C2 (uk) Спосіб отримання похідних 1-(2-галогенбіфеніл-4-іл)-циклопропанкарбонової кислоти
IN2012DN03032A (fr)
UA106386C2 (ru) Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
IN2012DN01929A (fr)
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
WO2012063115A3 (fr) Procédé de préparation de rosuvastatine calcique via un nouvel intermédiaire amine
IN2014DN10209A (fr)
UA110626C2 (uk) Спосіб одержання пан-інгібіторів циклінзалежної кінази формули (i), а також проміжні продукти цього процесу одержання